175 related articles for article (PubMed ID: 34988055)
61. The trend in quality of life of Chinese population: analysis based on population health surveys from 2008 to 2020.
Wang D; Xie S; Wu J; Sun B
BMC Public Health; 2023 Jan; 23(1):167. PubMed ID: 36694154
[TBL] [Abstract][Full Text] [Related]
62. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
63. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
64. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
[TBL] [Abstract][Full Text] [Related]
65. Validity and reliability of the EQ-5D-3L (a generic preference-based instrument used for calculating quality-adjusted life -years) for patients with type 2 diabetes in Iran.
Zare F; Ameri H; Madadizadeh F; Aghaei MR
Diabetes Metab Syndr; 2021; 15(1):319-324. PubMed ID: 33486224
[TBL] [Abstract][Full Text] [Related]
66. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
67. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
Madan J; Khan KA; Petrou S; Lamb SE
Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
[TBL] [Abstract][Full Text] [Related]
68. The predictive ability of EQ-5D-3L compared to the LACE index and its association with 30-day post-hospitalization outcomes.
Al Sayah F; McAlister FA; Ohinmaa A; Majumdar SR; Johnson JA
Qual Life Res; 2021 Sep; 30(9):2583-2590. PubMed ID: 33974221
[TBL] [Abstract][Full Text] [Related]
69. EQ-5D-5L Population Norms and Health Inequality in Colombia.
Bailey HH; Janssen MF; Varela RO; Moreno JA
Value Health Reg Issues; 2021 Dec; 26():24-32. PubMed ID: 33773292
[TBL] [Abstract][Full Text] [Related]
70. Comparison of the psychometric properties of the EQ-5D-3L and SF-6D in the general population of Chengdu city in China.
Zhao L; Liu X; Liu D; He Y; Liu Z; Li N
Medicine (Baltimore); 2019 Mar; 98(11):e14719. PubMed ID: 30882636
[TBL] [Abstract][Full Text] [Related]
71. Construct validity and reliability of EQ-5D-3L for stroke survivors in a lower middle income setting.
Mahesh PKB; Gunathunga MW; Jayasinghe S; Arnold SM; Senanayake S; Senanayake C; De Silva LSD; Kularatna S
Ceylon Med J; 2019 Jun; 64(2):52-58. PubMed ID: 31455067
[TBL] [Abstract][Full Text] [Related]
72. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
73. Convergent and discriminative validity of the Frail-VIG index with the EQ-5D-3L in people cared for in primary health care.
Zamora-Sánchez JJ; Zabaleta-Del-Olmo E; Gea-Caballero V; Julián-Rochina I; Pérez-Tortajada G; Amblàs-Novellas J
BMC Geriatr; 2021 Apr; 21(1):243. PubMed ID: 33849481
[TBL] [Abstract][Full Text] [Related]
74. Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L.
Rand K; Arnevik EA; Walderhaug E
J Patient Rep Outcomes; 2020 Nov; 4(1):92. PubMed ID: 33165764
[TBL] [Abstract][Full Text] [Related]
75. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
76. Reliability and validity of the EQ-5D-3L for Kashin-Beck disease in China.
Fang H; Farooq U; Wang D; Yu F; Younus MI; Guo X
Springerplus; 2016; 5(1):1924. PubMed ID: 27917330
[TBL] [Abstract][Full Text] [Related]
77. Psychometric Properties of EQ-5D-3L and EQ-5D-5L in Cognitively Impaired Patients Living with Dementia.
Michalowsky B; Hoffmann W; Xie F
J Alzheimers Dis; 2021; 83(1):77-87. PubMed ID: 34275901
[TBL] [Abstract][Full Text] [Related]
78. Reporting and valuing one's own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition.
Ernstsson O; Burström K; Heintz E; Mølsted Alvesson H
Health Qual Life Outcomes; 2020 Dec; 18(1):388. PubMed ID: 33334348
[TBL] [Abstract][Full Text] [Related]
79. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
80. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
